The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry.
Antidepressant
Maintenance
Safety
Side effects
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
23
09
2021
revised:
01
03
2022
accepted:
06
04
2022
pubmed:
12
4
2022
medline:
25
5
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
On a background of the rapidly expanding clinical use of ketamine and esketamine for treatment of depression and other conditions, we examined safety monitoring, seeking to identify knowledge gaps relevant to clinical practice. An international group of psychiatrists discussed the issue of safety of ketamine and esketamine and came to a consensus on key safety gaps. There is no standard safety monitoring for off-label generic ketamine. For intranasal esketamine, each jurisdiction providing regulatory approval may specify monitoring. Treatment is often provided beyond the period for which safety has been demonstrated, with no agreed framework for monitoring of longer term side effects for either generic ketamine or intranasal esketamine. The KSET has established face and content validity, however it has not been validated against other measures of safety. We recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side effects.
Identifiants
pubmed: 35405177
pii: S0165-0327(22)00357-3
doi: 10.1016/j.jad.2022.04.020
pmc: PMC9133168
mid: NIHMS1798675
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-46Subventions
Organisme : Intramural NIH HHS
ID : ZIA MH002857
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
Psychother Psychosom. 2021;90(1):41-48
pubmed: 32854103
JAMA Psychiatry. 2019 Sep 1;76(9):893-903
pubmed: 31166571
Pharmacol Rep. 2020 Jun;72(3):543-562
pubmed: 32301056
BMJ Case Rep. 2021 Jan 25;14(1):
pubmed: 33495180
J Affect Disord. 2020 Apr 1;266:615-620
pubmed: 32056935
Bipolar Disord. 2021 Jun;23(4):426-428
pubmed: 33587793
Int J Neuropsychopharmacol. 2016 Apr 20;19(4):
pubmed: 26578082
Psychol Med. 2015 Mar;45(4):693-704
pubmed: 25010396
Acta Psychiatr Scand. 2016 Jul;134(1):48-56
pubmed: 27028832
Am J Psychiatry. 2019 May 1;176(5):401-409
pubmed: 30922101
J Affect Disord. 2021 Jan 1;278:542-555
pubmed: 33022440
Psychother Psychosom. 2021;90(2):138-139
pubmed: 33108791
J Clin Psychiatry. 2020 Apr 21;81(3):
pubmed: 32316080
Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582
pubmed: 32078034
Am J Psychiatry. 2018 Jul 1;175(7):620-630
pubmed: 29656663
J Affect Disord. 2020 Nov 1;276:660-666
pubmed: 32871698
Am J Psychiatry. 2019 Jun 1;176(6):428-438
pubmed: 31109201
Lancet Psychiatry. 2018 Jan;5(1):65-78
pubmed: 28757132